10559 results for 'IL-28 R alpha/IFN-lambda R1'

For decades, we viewed cancer as a rogue army of cells, a biological glitch driven solely by genetic mutations and metabolic greed. We imagined tumors as isolated fortresses, growing in a vacuum of t

Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst

Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does

Written by Seán Mac Fhearraigh, PhD  •  Updated: 19 May 2026  •  ~10 min read Quick Answer A sandwich ELISA uses two antibodies — a capture ant

By Sophie Arthur How many diseases and conditions do you think exist in this world? Thousands? Hundreds of thousands? Maybe even millions? Unfortunately, I don’t know the answer. But what I

B7-H3, also known as CD276, is a member of the B7 family of immune checkpoint molecules that has emerged as a compelling target in tumor immunotherapy. Initially recognized for its role i

Quick Facts About SirexatamabWhat is Sirexatamab?Sirexatamab is an investigational monoclonal antibody designed to target CD47, a key immune checkpoint involved in cancer evasion.How Doe

Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen

Quick Facts About LemzoparlimabWhat is Lemzoparlimab?Lemzoparlimab is a monoclonal antibody that targets CD47, a protein known for its role in helping tumors evade the immune system. By

Quick Facts About NadecnemabWhat is Nadecnemab?Nadecnemab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint protein involved in cancer evasion.How Does

Protocole ELISA contre les anticorps hétérophiles en clinique et labo Un résultat Elisa qui ne colle pas au tableau clinique évoque d’abord une interférence par anticorps hétérophiles, surtout sur un

Shane O’Grady, PhD student, RCSI Cancer is a disease that will, unfortunately, touch all of our lives at some point, directly or indirectly. Despite decades

Introduction to KIR Blockade in Cancer ImmunotherapyNatural killer (NK) cells are crucial components of the innate immune system, responsible for recognizing and destroying virally infec

By Anusha Senevirante, Post-Doctoral researcher, Imperial College London With non-communicable diseases (or NCDs, which include heart disease, diabetes, ca

Agata Miezaniec PhD Candidate, University of Nottingham, UK Epigenetics and the link to DNA Methylation The term ‘Epigenet

Why do powerful cancer immunotherapies work wonders for some patients but fail for others? The answer may lie not just in the cancer cells themselves, but in the energy levels of our own immune warrio

Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne

Cell Signalling · Kinase CascadesMAPK Signaling: The Pathway of Mitogen StimulationThe mitogen-activated protein kinase (MAPK) pathway is one of the most important signalling cascades in biology, conv

A depletion experiment is only as good as the depletion you can prove. Injecting a functional-grade antibody and assuming the population is gone is the most common failure mode in in vivo immunology.

By Dr. Niclas Thomas “Data science” is a recent addition to the vocabulary of analytics, and can mean many different things to different people. As far as